Drug Combo Proves Powerful Against Lung Cancer Troy NY

A two-drug combination treatment in Troy proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

James C Arseneau
(518) 489-0044
400 Patroon Creek Blvd
Albany, NY
Stephen Hillinger
(518) 489-0044
400 Patroon Creek Blvd
Albany, NY
STEWART SILVERS, MD
(518) 399-4600
896 Riverview Road
Rexford, NY
Joseph James Dudek, MD
518-489-0044
317 S Manning Blvd Ste 310
Albany, NY
Stewart Alan Silvers, MD
518-399-4600
896 Riverview Rd
Rexford, NY
Ankesh Nigam
(518) 262-5623
47 New Scotland Ave
Albany, NY
Lawrence Garbo
(518) 489-0044
400 Patroon Creek Blvd
Albany, NY
ANNE NEPO, MD
(518) 262-5513
47 New Scotland Avenue
Albany, NY
JOHN FERRARO, MD
(518) 786-3122
1003 Louden
Cohoes, NY
Todd Harrison Doyle, MD
518-525-1404
317 S Manning Blvd Ste 100
Albany, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Risks for Childhood Cancer Survivors Troy NY
People who survived cancer as children face a high lifelong risk for developing another cancer, a new study has found. A study that appears online May 26 in the Journal of the National Cancer Institute went further than earlier studies by following people from birth through age 79. The researchers analyzed data on more than 47,000 people who had been diagnosed with cancer before the age of 20.
- Hormone Therapy for Breast Cancer Troy NY
- Genetic Clues for Skin Cancer Therapies Troy NY
- Delayed Prostate Cancer Therapy Troy NY
- Side Effect Of Chemotherapy Drugs Troy NY
- Fungal Infection Treatments Troy NY
- Exercise for Breast Cancer Survival Troy NY
- Hormone Therapy for Lung Cancer Troy NY
- Exercise for Prostate Cancer Troy NY